US FDA has approved epoetin alfa-epbx as a biosimilar of epoetin alfa for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. The following article details the highlights of prescribing information for the drug.
Indications And Usage Epoetin alfa-epbx is an erythropoiesis-stimulating agent (ESA) indicated for: Anemia caused due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis Zidovudine in patients with HIV-infection The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery Limitations of Use: Epoetin alfa-epbx has not been shown to improve quality of life, fatigue, or patient well-being. Dosage…
